This led to the development of samalizumab (ALXN6000), a first-in-class anti-CD200 antibody tested in phase I clinical trials for multiple myeloma and chronic lymphocytic leukaemia by Alexion Pharmaceuticals [48]. This evidence concerns the gene CD200 and B-cell chronic lymphocytic leukemia.